All In Biotech

Drug Trial Radar · NCT07881211

A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies

A First-in-Human, Phase 1, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-T0050 in DLBCL and Other Aggressive B-Cell Malignancies

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Oct 31, 2029

Study completion Oct 31, 2029

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Oct 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety and tolerability of BG-T0050 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in adults with DLBCL and other aggressive B-cell malignancies

Conditions

  • Diffuse Large B-Cell Lymphoma
  • B-Cell Malignancies

Interventions

  • BG-T0050Drug

    Administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1a Dose Escalation: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: Approximately 1 Month
  2. Part 1a and Part 1b: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)Time frame: From first dose until 30 days after the last dose; approximately 13 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.